DENGUE viruses, types 1–4, are arthropod-borne flaviviruses which cause dengue shock syndrome (DSS) in humans possessing pre-infection antibody, passively acquired or derived from heterotypic infection1. Although the immuno-pathological mechanism of DSS is not fully understood, experimental studies suggest that dengue virus production is immunologically regulated. Monkeys with monotypic immunity to dengue types 1, 3 or 4 viruses, when challenged with dengue 2, had significantly higher levels of circulating virus than did similarly infected susceptible animals2. This may be attributable to the replication of virus in leukocytes. In infected monkeys, virus was frequently recovered from buffy coat cells and from lymphatic tissues3. The role of leukocytes in enhanced infection is further supported by the observation that dengue replicates readily in cultures of peripheral blood leukocytes (PBL) prepared from immune simian or human donors, but poorly or not at all in leukocytes from non-immune hosts4–6. Studies on the immunological specificity of this phenomenon have been hindered by the requirement either for expensive experimental hosts (monkeys) or for human donors with chronologically defined dengue infections. Here we describe the in vitro enhancement of dengue infection in PBL by antibody. This system provides a provisional model for DSS in young infants during primary dengue infections7,8.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Halstead, S. B. Yale J. Biol. Med. 42, 350–362 (1970).
Halstead, S. B., Shotwell, H. & Casals, J. J. infect. Dis. 128, 15–22 (1973).
Marchette, N. J., Halstead, S. B., Falkler, W. A. Jr., Stenhouse, A. C. & Nash, D. R. J. infect. Dis. 128, 23–30 (1973).
Halstead, S. B., Chow, J. & Marchette, N. J. Nature, new Biol. 243, 24–26 (1973).
Marchette, N. J., Halstead, S. B. & Chow, J. S. J. infect. Dis. 133, 274–282 (1976).
Halstead, S. B., Marchette, N. J., Chow, J. S. S. & Lolekha, S. Proc. Soc. exp. Biol. Med. 151, 136–139 (1976).
Halstead, S. B., Scanlon, J. E., Umpaivit, P. & Udomsakdi, S. Am. J. trop. Med. Hyg. 18, 987–1021 (1969).
Halstead, S. B., Nimmannitya, S. & Cohen, S. N. Yale J. Biol. Med. 42, 311–328 (1970).
Halstead, S. B., Udomsakdi, S., Simasthien, P., Singharaj, P., Sukhavachana, P. & Nisalak, A. Yale J. Biol. Med. 42, 261–275 (1970).
Halstead, S. B., Casals, J., Shotwell, H. & Palumbo, N. Am. J. trop. Med. Hyg. 22, 365–374 (1973).
Brandt, W. E., Buescher, E. L. & Hetrick, F. M., Am. J. trop. Med. Hyg. 16, 339–347 (1967).
Sartorelli, A. C., Fischer, D. S. & Downs, W. G. J. Immun. 96, 676–682 (1966).
De Madrid, A. T. & Porterfield, J. S. Bull. Wld Hlth Org. 40, 113–121 (1969).
Böyum, A. Scand. J. clin. Lab. Invest. 21 suppl. 97, 77–89 (1968).
Halstead, S. B. Am. J. trop. Med. Hyg. 23, 974–982 (1974).
Allison, A. C. Progr. med. Virol. 18, 15–31 (1974).
Simmons, J. S., St. John, J. H. & Reynolds, F. H. K. Philipp. J. Sci. 44, 1–251 (1931).
Porter, D. D. & Larsen, A. E. Prog. med. Virol. 18, 32–47 (1974).
Hawkes, R. A. & Lafferty, K. J. Virology 33, 250–261 (1967).
Kjellén, L. E. & Schlesinger, R. W. Virology 7, 236–239 (1959).
Azuma, M. Arch. ges. Virus 41, 11–19 (1973).
About this article
Cite this article
HALSTEAD, S., O'ROURKE, E. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265, 739–741 (1977). https://doi.org/10.1038/265739a0
Current Opinion in HIV and AIDS (2021)
Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships
Journal of Pharmaceutical Sciences (2021)
Persistence of Human Bocavirus 1 in Tonsillar Germinal Centers and Antibody-Dependent Enhancement of Infection
Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys